Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
With
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological confirmation of adenocarcinoma of the colon or rectum
Tumor tissue sample available for KRAS and BRAF assessment
Measurable metastatic Stage IV disease including at least one measurable lesion that has not previously been radiated
No prior chemotherapy for metastatic CRC
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Life expectancy of at least 12 weeks
Adequate bone marrow, liver, and renal function; adequate clotting parameters
You may not be if
Prior treatment with sorafenib
Clinical or radiographic evidence of brain metastasis
Major surgery, surgical biopsy, or significant traumatic injury within 28 days of randomization; evidence or history of bleeding diathesis or coagulopathy
Red blood cell (RBC), white blood cell (WBC), or platelet transfusions and/or growth factor use within 28 days before randomization
Adjuvant therapy for CRC (Stage I, II, or III) completed within 12 months before randomization
Serious, non-healing wound, ulcer, or bone fracture; Grade 3 or 4 hemorrhage within 28 days before randomization
Use of anticoagulation therapy (low dose anticoagulation therapy to mitigate risk of thrombosis due to placement of a semi-permanent central venous port for administration of chemotherapy is allowed. The use of coumadin and related compounds is excluded.)
Uncontrolled hypertension (systolic blood pressure \> 150 mmHg or diastolic pressure \> 100 mmHg on repeated measurement) despite optimal medical management
Thrombolic, embolic, venous, or arterial events (eg, cerebrovascular accident, including transient ischemic attacks) within 6 months before randomization
Active cardiac disease including:
* Congestive heart failure
* Unstable angina or myocardial infarction within the 6 months before randomization
